Neumora Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(184,968) | $(127,195) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 30,087 | 11,189 |
| Non-cash operating lease expense | 2,436 | 2,469 |
| Depreciation and amortization | 474 | 502 |
| Net accretion of investments in marketable securities | (4,638) | (3,068) |
| Other noncash expenses | 21 | 54 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 15,306 | (3,274) |
| Accounts payable | 5,770 | 1,331 |
| Accrued liabilities | 5,401 | 8,646 |
| Operating lease liabilities | (2,485) | (2,490) |
| Net cash used in operating activities | (132,596) | (111,836) |
| Investing activities: | ||
| Purchases of marketable securities | (205,324) | (89,000) |
| Proceeds from maturities of marketable securities | 234,341 | 139,783 |
| Cash paid for acquisition of assets | (775) | — |
| Purchases of property and equipment | — | (73) |
| Net cash provided by investing activities | 28,242 | 50,710 |
| Financing activities: | ||
| Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions | — | 232,565 |
| Proceeds from exercise of stock options | 6,255 | 2,517 |
| Proceeds from issuance of common stock | — | 810 |
| Repurchase of unvested early exercised shares | — | (491) |
| Payments for offering costs in connection with at-the-market offering and initial public offering | (225) | (2,984) |
| Net cash provided by financing activities | 6,030 | 232,417 |
| Net change in cash and cash equivalents and restricted cash | (98,324) | 171,291 |
| Cash and cash equivalents and restricted cash at beginning of year | 375,251 | 242,206 |
| Cash and cash equivalents and restricted cash at end of period | $276,927 | $413,497 |
| Components of cash and restricted cash: | ||
| Cash and cash equivalents | $275,714 | $412,284 |
| Restricted cash | 1,213 | 1,213 |
| Total cash and cash equivalents and restricted cash | $276,927 | $413,497 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $473 | $— |
| Offering costs in connection with at-the-market offering included in accrued liabilities | $321 | $— |
| Conversion of preferred stock into common stock upon completion of initial public offering | $— | $843,687 |
| Offering costs related to initial public offering included in accounts payable and accrued liabilities | $— | $2,963 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.